HOME > INVESTOR > ARCHIVES > PRESS RELEASE
December 2016
Lupin Receives Tentative Approval for Generic Livalo® Tablets
Date: December 30
Lupin Receives Tentative Approval for Generic Giazo® Tablets
Date: December 29
Lupin Receives Tentative Approval for Generic Benicar® Tablets
Date: December 26
Lupin Launches Generic Vfend® Tablets and Vfend® Oral Suspension in the US
Date: December 19
Lupin Receives FDA Approval for Generic Topicort® Ointment, 0.05%
Date: December 14
Lupin Receives FDA Approval for Generic Topicort® Ointment
Date: December 06
Lupin Receives Tentative Approval for Generic Zorvolex® Capsules
Date: December 06
Lupin Receives FDA Approval for Generic Norco® Tablets
Date: December 05
Lupin and Eli Lilly Expand Partnership in India
Date: December 01
November 2016
Lupin Receives FDA Approval for Generic Nuvigil® Tablets
Date: November 29
Lupin Receives Tentative Approval for Generic Epzicom® Tablets
Date: November 23
Lupin Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
Date: November 17
Lupin Launches Generic Activella® Tablets in the US
Date: November 15
Lupin Launches Novel Injectable Iron Formulation Under Brand Names “ISOFER” and “JILAZO” in India
Date: November 11
Lupin's Quarter II, FY2017 - Results
Date: November 09
Lupin receives EIR from US FDA for Goa, March 2016 Inspection
Date: November 4
Lupin Receives FDA Approval for Generic Ortho-Cyclen® 28 Tablets
Date: November 1
October 2016
Notice to the Exchanges on Board Meetings.
Date: October 18
Type 2 Diabetes: Boehringer Ingelheim India and Lupin Announce Strategic Co-marketing Agreement
Date: October 13
Lupin and Monosol Rx announce licensing agreement for multiple pediatric-focused products
Date: October 06
September 2016
Lupin Receives FDA Approval for Generic Namenda XR® Capsules
Date: September 29
Lupin Receives Tentative Approval for Generic Rapaflo® Capsules
Date: September 06
Lupin Receives Tentative Approval for Generic Avelox® Tablets
Date: September 06
Lupin Receives Tentative Approval for Generic Zithromax® Oral Suspension
Date: September 01
August 2016
Lupin Receives Tentative Approval for Generic Paxil CR® Tablets
Date: August 26
Lupin Receives FDA Approval for Generic Zyvox® Tablets
Date: August 24
Lupin Receives Approval for Acotiamide Tablets to Treat Functional Dyspepsia
Date: August 22
Lupin Receives FDA Approval for Potassium Chloride Extended-Release Capsules
Date: August 17
Notice to the Exchanges on Board Meeting
Date: August 11
Lupin Receives FDA Approval for Generic Klor-Con® Extended-Release Tablets
Date: August 10
Record Sales & Profits - Quarter I FY2017
Date: August 9
Lupin Acquires Branded Product Portfolio from Shionogi in Japan
Date: August 2
July 2016
Lupin Receives Tentative Approval for Generic Lexiva® Tablets, 700 mg from US FDA
Date: July 27
Lupin Launches Generic Ortho Tri-Cyclen® Tablets in the US
Date: July 20
US FDA Audit at Lupin’s Dabhasa Facility, 29th June – 06th July 2016
Date: July 8
Lupin receives EIR from US FDA for Goa, July 2015 Inspection
Date: July 7
June 2016
Lupin Receives FDA Approval for Generic Activella® Tablets
Date: June 22
Lupin Appoints Yugesh Goutam as President – Global HR
Date: June 7
Lupin Receives FDA Approvals for Generic Vfend® Tablets 50mg, 200mg & Vfend® Oral Suspension, 40 mg/mL
Date: June 6
May 2016
Lupin announces closure of US FDA Audits for its Mandideep and Aurangabad Facilities
Date: May 26
Record Sales & Profits – A New High Quarter IV & Annual Results - FY2016
Date: May 19
Notice to the Exchanges on Board Meetings
Date: May 04
April 2016
Lupin Launches Generic Femhrt® Tablets in the US
Date: April 18
Lupin to Market new Inhaler under the brand name Loftair® in India
Date: April 11
Lupin named amongst AON Best Employers India 2016
Date: April 05
Lupin Appoints Dr. Kurt Nielsen as President of Lupin - Somerset
Date: April 05
Lupin Launches Generic Intermezzo® Sublingual Tablets in the US
Date: April 05
March 2016
Lupin Launches Generic Aricept® Tablets in the US
Date: March 31
Disclosures to the Exchanges on Mandideep US FDA Audit
Date: March 29
Disclosures to the Exchanges on Goa US FDA Audit
Date: March 15
Lupin Completes its Acquisition of GAVIS
Date: March 09
 
February 2016
Quarter III Results, FY2016
Date: February 05
Lupin Launches Generic Glumetza® HCI ER Tablets in the US
Date: February 02
January 2016
Notice to the Exchanges on Board Meetings
Date: January 19
Lupin Receives FDA Approval for Generic Generess® Tablets
Date: January 08
Lupin Launches Generic Ortho Tri-Cyclen® Lo Tablets
Date: January 06